Mostrar el registro sencillo del ítem
| dc.contributor.author | Gallego-Ortega, Alejandro | |
| dc.contributor.author | Galindo-Romero, Caridad | |
| dc.contributor.author | Vidal-Villegas, Beatriz | |
| dc.contributor.author | Bernal-Garro, José-Manuel | |
| dc.contributor.author | de-la-Villa, Pedro | |
| dc.contributor.author | Avilés-Trigueros, Marcelino | |
| dc.contributor.author | Vidal-Sanz, Manuel | |
| dc.date.accessioned | 2026-03-10T11:49:08Z | |
| dc.date.available | 2026-03-10T11:49:08Z | |
| dc.date.issued | 2025-04 | |
| dc.identifier.citation | Gallego-Ortega A, Galindo-Romero C, Vidal-Villegas B, Bernal-Garro JM, De La Villa P, Avilés-Trigueros M, et al. The action of 7,8-dihydroxyflavone preserves retinal ganglion cell survival and visual function via the TrkB pathway in NMDA-induced retinal excitotoxicity. Biomedicine & Pharmacotherapy. abril de 2025;185:117944. doi:10.1016/j.biopha.2025.117944 | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/25212 | |
| dc.description.abstract | PURPOSE: To analyze the response of different retinal ganglion cell (RGC) populations to NMDA-induced retinal excitotoxicity and the effect of an intraperitoneal treatment with 7,8-Dihydroxyflavone (DHF), a potent selective TrkB agonist. METHODS: Adult albino rats were treated the day prior to NMDA injection and the three following days with intraperitoneal vehicle (1?%DMSO in 0.09?%NaCl) or DHF (5 mg/kg in vehicle) injections. DHF-afforded protection was studied in the population of Brn3a(+)RGCs, OPN(+)RGCs (?-RGCs), OPN(+) Tbr2(+)RGCs (?ONs-RGCs), OPN(+) Tbr2(-)Brn3a(-)RGCs (?ONt-RGCs) and OPN(+)Brn3a(+)RGCs (?OFF-RGCs) at 3,7,14, or 21 days. The functional response was analyzed longitudinally with full-field electroretinograms. The mechanisms underlying DHF-afforded neuroprotection were assessed by western blot (WB) analysis of the levels of phosphorylated and total TrkB, phosphatidylinositol 3 kinase (PIK3/AKT) and mitogen-activated protein kinase (MAPK). RESULTS: NMDA intravitreal injection resulted in a significant diminution of the mean amplitudes of the pSTR and b-waves, as well as in severe depletion of all RGCs studied except ?ONt-RGCs. DHF treatment resulted in rescued mean amplitudes of the pSTR and b-waves up to 21 days after NMDA. WB analysis revealed an increase in p-TrkB which correlates to the increase of TRKB protein and an increase in normalized pAKT/AKT. pMAPK/MAPK was upregulated earlier and significantly higher in DHF-treated retinas. DHF afforded survival of up to 49?% of the Brn3a(+)RGCs versus 25?% of the vehicle group at 21 days after NMDA, and improved survival of the ?-RGC and ?ONs-RGCs but did not rescue the ?OFF-RGCs. CONCLUSION: Different RGC types exhibit variable susceptibilities to NMDA injury, and DHF-mediated activation of TrkB affords neuroprotection. | |
| dc.language.iso | eng | |
| dc.publisher | ELSEVIER | |
| dc.rights | Atribución/Reconocimiento 4.0 Internacional | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/deed.es | |
| dc.subject.mesh | Animals | |
| dc.subject.mesh | Retinal Ganglion Cells/drug effects/metabolism/pathology | |
| dc.subject.mesh | N-Methylaspartate/toxicity | |
| dc.subject.mesh | Flavones/pharmacology | |
| dc.subject.mesh | Receptor, trkB/metabolism | |
| dc.subject.mesh | Cell Survival/drug effects/physiology | |
| dc.subject.mesh | Rats | |
| dc.subject.mesh | Signal Transduction/drug effects | |
| dc.subject.mesh | Male | |
| dc.subject.mesh | Neuroprotective Agents/pharmacology | |
| dc.subject.mesh | Electroretinography | |
| dc.subject.mesh | Vision, Ocular/drug effects | |
| dc.subject.mesh | Retina/drug effects | |
| dc.title | The action of 7,8-dihydroxyflavone preserves retinal ganglion cell survival and visual function via the TrkB pathway in NMDA-induced retinal excitotoxicity. | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 40056826 | |
| dc.relation.publisherversion | https://linkinghub.elsevier.com/retrieve/pii/S0753332225001386 | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | |
| dc.identifier.doi | 10.1016/j.biopha.2025.117944 | |
| dc.journal.title | Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie | |
| dc.identifier.essn | 1950-6007 |